James Pursley, president of Hinge Health Inc. (NASDAQ: HNGE), sold 33,000 shares of Class A common stock for $2,905,663 on August 21, 2025, executed under a Rule 10b5-1 trading plan adopted June 13, 2025.
The transactions occurred across four blocks at weighted average prices between $84.80 and $88.68 per share. The first block of 500 shares was sold for $42,401 at an average price of $84.80, leaving Pursley with 738,735 shares. The second block of 6,300 shares generated $549,559 at $87.23 per share, reducing his holdings to 732,435 shares. The largest block, 22,789 shares, yielded $2,011,942 at $88.25 per share, lowering his stake to 709,646 shares. The final block of 3,411 shares produced $302,561 at $88.68 per share, ending with 706,235 shares held.
Hinge Health’s stock was trading at $89.98 at the time of the report, down $2.28 or 2.53% in real-time data, and near its 52-week high of $93.13. The company’s shares have surged 121% over the past six months, though InvestingPro ranks it as the most overvalued in its coverage universe relative to fair value.
The disposal follows strong second-quarter results, with earnings of $0.59 per share exceeding Wall Street estimates of $0.13 and revenue rising 53% year-over-year to $212.8 million. Hinge Health also raised its full-year 2026 revenue and profit guidance and announced a $105 million acquisition of Cylinder Health to expand into gastrointestinal health.
Analysts have adjusted price targets upward in response. Citizens raised its target to $107, Truist Securities set a new target at $112, and Stifel increased its target to $96.
